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ABSTRACT
Amgen is a leader in the biopharmaceutical industry. It manufacturers and provides human
therapeutics that drastically improve lives. Amgen's reputation and brand, its goodwill, is an
invaluable asset to its ability to succeed in an increasingly competitive landscape. Because of this, risk
management, both in manufacturing and in supply chain arenas, are directly linked to continuing
long-term sustainable growth. With an increasingly global market and expanding pipelines,
biotechnology companies, like Amgen, face a supply chain challenge to manufacture and distribute
products using economically feasible methods that ensure patient safety. Preventing product mix-ups
plays a key role in ensuring that safety.
Marking nude product that moves intra-Amgen or to contract manufacturers will provide a higher
level of confidence that the right product is reaching the patient. Several solutions for marking nude
vials and syringes immediately rise to the top of the strata of potential technologies. Despite being
promising, each technological solution has key unknowns that must be answered by rigorous lab-
scale testing to provide quantitative data to make the best decision on the future of this process
within Amgen. Along with the testing, it is clear that the financial landscape of the different solutions
varies a great deal. Each potential solution will be analyzed to determine its capital requirements as
well as ongoing costs. Lastly, the solution must be realistic to implement into Amgen's current GMP.
And thus, each technology will be evaluated as it relates to the overall complexity of implementation
into an already tightly controlled process.
From a more macroscopic industry perspective, the FDA, as well as other regulatory agencies, has
been discussing this issue for several years. Strategically, biotechnology companies are all hesitant to
invest in a particular solution at the moment for fear that the FDA will require a different solution in
the near term. In reality, biotechnology companies risk billions in R&D and drug development and
are therefore, in a way, naturally risk averse when it comes to their processes and operations.
Inventory and manufacturing operations are more driven by risk management than by cost. Of
course, the important factor to remember is that risk management is a precursor to drug quality and
patient safety. The majority of the risks that are controlled are risks that would either prevent
environmental contamination of the drugs or affect the quality of the drugs. Altruistic or not, this has
profound long term business strategy implications in an ultra-competitive marketplace where another
biotechnology firm would certainly oblige taking market share if Amgen were to suffer a reputation
ruining event.
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GLOSSARY
cGMP - current Good Manufacturing Practice
EMEA - European Agency for the Evaluation of Medicinal Products
RFID - Radio Frequency Identification
2D Matrix Barcode - A two-dimensional barcode with the capability of holding many
digits of information.
DP&DD - Drug Product and Device Development
AML - Amgen Manufacturing Limited
ABR - Amgen Breda
EU - European Union
EOQ - Economic Order Quantity
Fill-Finish - The process by which bulk drug product is filled into the primary packaged
and then labeled and packaged.
WIP - Work in Progress
DOE - Design of Experiments
1 Introduction
1.1 Project Drivers
With an increasingly global market and expanding pipelines, biotechnology
companies like Amgen face a supply chain challenge to manufacture and distribute products
using economically feasible methods that ensure patient safety. Preventing product mix-ups
is a key arena for ensuring that safety. Many precautions and steps are taken to ensure the
highest quality product. Both the product and the glass are inspected 100% at specific points
throughout the process either by a human inspector or by a specially designed inspection
machine. Precise procedures are in place that governs how product is packaged, handled and
labeled. Procedures in product handling require physical counts of incoming and outgoing
product to match. These actions are taken to minimize and mitigate the risk both in the
manufacturing process but also in the supply chain.
Amgen's aspiration to completely mitigate all risk is strongly driven by industry and
consumer dynamics. In the biopharmaceutical industry, because of the immense financial
risk involved in upstream research and development, Amgen hedges its risk in many other
areas. For example, Amgen has qualified contract manufacturers on hand if anything were to
interrupt the production of its products. As an illustrative example of the why this is so
important, in June 2009, Genzyme "halted production of two drugs for rare genetic
disorders after a virus was discovered in production equipment at its Allston [MA] plant. As
a result of the plant's shutdown, the Cambridge-based company said, Cerezyme patients could
go without one or two treatments, while those taking Fabrazjme may need to skip up to four
doses. Patients usually receive the drugs intravenously every two weeks."' Now, uniquely,
Genzyme has no competition for these drugs so it will not suffer loss of market share, just
lost revenues from the forced missed doses. Yet still, "some industry watchers and patients
fault the company for not having enough drug inventory on hand to keep patients from
missing doses of the enzyme treatments."'
Amgen's supply chain consists of two main arenas: North America and the EU (see
Figure 1). While the separating the world between only two main areas might seem grossly
lacking, it is important because of how product flows to these two areas from the
manufacturing or fill-finish facility. Product destined for North America is filled, finished,
labeled and packaged for consumer sale all prior to shipping. In contrast, product destined
for Europe, for example, is filled and finished in Puerto Rico then shipped nude in WIP
packaging. Once at the European facility, the product is then labeled and packaged for
consumer use. It is this latter scenario where risk is inherent in the process. Because all of
Amgen's products look identical and for the most part are packaged in the same primary
container (a 3cc vial or a 1mL syringe), there is the potential for product mix-up or
mislabeling.
BREAKDOWN OF THE WORLD PHARMACEUTICAL MARKET - 2007 SALES
North America (USA, Canada)
45.9% . Europe
- Japan
Africa, Asia (excluding Japan) & Australia
E] Latin America
Note: Europe includes non-EU members and CIS markets
Source: IMS Health, February 2008 (data relate to the 2007 audited market at
ex-factory prices)
Figure 1: World Pharmaceutical Market by Sales
What drives the need to delay labeling is a function of flexibility. The Puerto Rico
facility is set-up to run labeling operations for large batches of product all destined for the
largest market in the world, the US. Although Europe is the second largest pharmaceutical
market, it is a conglomeration of many different countries which all have different language
and labeling requirements. Amgen's European labeling and distribution facility was set up to
handle small batches and large numbers of labeling changeovers. Another component of
flexibility is the function of customization postponement or delaying country specific
packaging until closer to the point of sale. An example from the Sloan Management Review,
"a US computer manufacturer makes printers for worldwide distribution. The printers have
a few country-specific components, such as the power supply and owner's manual. The U.S.
factory produces to meet demand forecasts, but by the time the printers reach regional
distribution centers, demand has changed. Because the printers have been prepared for
specific countries, the distribution centers have no flexibility to respond to changing demand
patterns. The result is simultaneously high inventory stockpiles and backlogs." 2 On top of
these problems, biotechnology companies have to also be concerned about shelf life and
expiration dates of their products. While a simple example from different industry, it sheds
light on the motivation for biopharmaceutical companies to delay labeling operations.
Indeed, this is an industry-wide risk that exists within Amgen's peer companies as
well. Regulatory bodies including state governments, the US Food and Drug Administration
(FDA) and the European Medicines Agency (EMEA) have all included recommendations
for the discontinuation of transport of unmarked product. (See Appendix 1 for the cGMP
regulatory framework.) As technologies improve and Amgen's pipeline of drugs in
development becomes commercialized, the need for a unit-level distinguishing mark
becomes increasingly important to mitigate a potentially large risk. If the entire drug
discovery, development and commercialization process is modeled as one long
manufacturing process, then the farther along in the process, the costlier the mistake for
Amgen. Thus, a mistake or mix-up after or during commercialization is much more
expensive than a mistake during discovery.
1.2 Problem Statement
Biotechnology companies currently approach unit-level marking technologies with
the belief that, in the very near future, some sort of unit-level identification and tracking will
be a regulatory requirement. It is already a regulatory expectation (see Appendix 1).
Although there is potential for this requirement plus the potential risk, biotechnology
companies have only just begun applying some marking technologies to their processes. The
purpose of this business case is to examine the industry of marking technologies and
determine if any feasible solutions exist. Amgen will be used as a representation of a large
biotechnology company so as to understand the variables required for implementing
marking technology in the industry.
1.3 Thesis Overview
Chapter 2
This chapter captures the background of the problem including company
information, state-of-the industry of marking technology as well as a benchmark
review of the current technologies and peer companies' marking processes.
Chapter 3
This chapter presents the hypothesis of this document.
Chapter 4
This chapter describes the methodology utilized as well as a decision framework for
choosing among the different technology options that can be used for other projects
within Amgen.
Chapters 5-7
These chapters present the laboratory tests and results of three most promising
technology options to mitigate the risk of product mix-up in the supply chain.
Chapter 8
This chapter discusses the various technological advancements that could impact the
landscape of marking technologies and options including LaserJet and plastic
primary packages.
Chapter 9
This chapter shows the financial and implementation repercussions of the solutions
to Amgen's internal operations. Specifically, the implementation focuses on clear
label technology.
Chapter 10
This chapter summarizes the results and presents conclusion remarks.
2 Background
2.1 Biopharmaceutical Industry
The biotechnology industry can trace its roots first to the 1953 Watson and Crick
discovery of the double-helix structure of DNA and second to the 1973 Cohen and Boyer
discovery of recombinant DNA cloning. The discovery of this genetic engineering
technology is considered the starting point for the biotech industry, which allowed scientists
to produce proteins from any organism in mass quantities. Venture capitalist Robert
Swanson partnered with Boyer to found Genentech, the first biotechnology company,
whose first product successes were around cloning the gene for human insulin and human
growth hormone.3 See a summary of the biopharmaceutical process below:
Raw InolOCumI
andrucon
----------------- 
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AtUpStream
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Figure 24: Biopharmaceutical Manufacturing Process
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Since this relatively modest almost niche beginning, the biotechnology industry has
grown at a furious pace fueled by the 1980 landmark U.S. Supreme Court decision to allow
the patent of bioengineered organisms. Now a dominating global industry, the
biotechnology industry currently has the following statistics:
Global biotechnology at a glance In 2008 (US$m)
G baUS Euro -Canada Pacifi
Revenues 66,127 16,515 2,041 4,965
R&D expense 25,270 5,171 703 601
Net income (loss) 417 (702) (1,143) (14)
Number of employees 128,200 49,060 7,970 15,530
Public companies __ 371 178 72 155
Public and private companies J 1,754 1,836 358 769
Table 15: Global Biotechnology Industry Statistics of 2008
Consolidation has since changed the face of the industry. Once dominated by a
flurry of start-ups throughout the late 1970s, 80s and 90s, the industry is increasingly a
function of merger and acquisition as well as alliance. The Merck/Schering-Plough,
Pfizer/Wyeth and Roche/Genentech mergers are all good examples of some of the biggest
firms merging. It seems that due to ever increasing costs of R&D as well as
commercialization have created the scenarios where indeed bigger is better. According to an
Innovation.org study from 2009, "To bring a new drug to market (from discovery through
clinical trials and FDA approval) costs an estimated $1 billion and can take 10 to 15 years or
longer. Only one in 10 new drugs that makes it into human testing actually makes it to
market. Given this high failure rate and the tremendous cost of bringing a new therapy to
market, companies depend on successful drugs to produce enough revenue to compensate
for both the R&D costs of the successful therapies and the expense of failed ones."
The figure below shows the timeline as well as costs for each phase of the development
process:
R&D Projects by Phase to Generate One Drug
Figure 37: Biopharmaceutical R&D Process
Industry experts from the publication BioQuality also report that both pharmaceutical and
biopharmaceutical companies believe that it is becoming more difficult to achieve product
approval due to longer trials, more stringent safety and efficacy requirements and a lengthier
review process. 6
With acquisitions like Pfizer/Wyeth and companies like Merck forming a
BioVentures unit in late 2008, the lines between traditional pharmaceutical and
biotechnology companies are blurring. Amgen's drug SENSIPAR is considered a small
molecule drug traditionally seen at pharmaceutical companies. Amgen's mission to become
the best therapeutics company is not indication or drug complexity specific. Increasing costs
and longer timelines for approval require that all companies in the biopharmaceutical space
become more adept are bringing any drug to market. These blurring lines between
pharmaceutical and biotechnology will continue to make waves throughout the industry in
the coming years.
2.2 Amgen, Incorporated
Amgen was founded in 1980 during the early days of the biotechnology industry.
Amgen's stated missions is to, "serve patients by transforming the promise of science and
biotechnology into therapies that have the power to restore health or even save lives." 2
Amgen's success began with the FDA approval of its first drug, an industry blockbuster
called EPOGEN in 1989, followed by another blockbuster NEUPOGEN in 1991, and both
P" rec ia
Years
anemia drugs. Amgen too is no stranger to acquisition and alliance. In the last ten years,
Amgen's growth has been largely a function of acquisition starting with the purchase of
Immunex in 2002. This purchase allowed Amgen to bring their next success, a rheumatoid
arthritis drug called ENBREL, to market. Since then, Amgen has grown from $3.5billion in
sales in 2002 to its 2008 mark of just shy of $15 billion. Today, it is the largest biotechnology
company in the world with just over 17,000 employees. It is headquartered in Thousand
Oaks, CA.
2.3 Current Challenges and Opportunities
Amgen, as well as the biotech industry as a whole, is facing serious challenges. In
2007, the FDA raised warnings concerning the risks of overuse of anemia drugs, a large part
of Amgen business. This led to a reduction in sales for that year as well as subsequent years
in that therapeutic area. Today, the global recession has started to affect even what some
industry experts say is a recession proof industry. One Amgen employee stated, "Biotech is
recession resistant, not recession proof." The massive increase in unemployment has led to
the loss of medical insurance coverage. This in turn has led to patients forgoing treatment
due to lack of funds. On top of that, healthcare reform is making its way through the
legislation process and could affect the reimbursement rates for certain Amgen drugs,
reducing its profits. Healthcare reform could also affect the length of patent protection
afforded biotechnology companies. With upfront investments in the billions, it is not
surprising biotechnology companies are pushing for the longest protection possible to
recoup their R&D costs. Facing these challenges, Amgen has renewed its focus on
operational excellence with a continued mission of serving patients and as shown in Figure 4
below, Amgen has a history of success in an industry where it is difficult to be operating in
the black.
All public
companieS
REVENUE
All public
companies except $25.2
Amgen
AD public $2 5
companies OEAN
All public
companies except
1980Amgen 2004
Figure 48: All Public Biotechnology Companies and Amgen
Amgen is in the process of bringing a new, internally developed post-menopausal
osteoporosis drug called PROLIA" to market. It is a drug that could drastically improve the
lives of its patients. Thus, it is a great opportunity for Amgen to immerge anew from the
challenges it has been facing with a new drug in a growing market. Along with PROLIAM7,
Amgen has what is considered to be one of the best drug development pipelines in the
biotech industry. Capitalizing on that pipeline will be paramount to Amgen's continued
success.
2.4 Parenteral Primary Packaging at Amgen
Biotechnology or biologic drugs are mainly administered parenterally or via a needle.
Drug product is presented to customers in one of two ways: vial or syringe. Vials generally
contain lyophilized or freeze dried product and the patient is provided a syringe filled with a
diluent such as WFI (water for injection). The patient then injects the vial with the diluent,
allowing the product to mix before puffing the product back into the syringe and finally
injecting the product into their body. Conversely and not surprisingly, the preferred primary
package is the pre-filled syringe, which is simply a syringe that already contains a single dose
in liquid form. Currently, for Amgen and for the biotech industry, both vials and syringes are
made of a specialized medical grade glass. Another important distinction between vials and
syringes is the method of purchase of each at Amgen. Vials are bought in bulk; meaning
Amgen completes the final sterilization of the vials prior to filling them with product.
Syringes are bought pre-sterilized and therefore need no further processing prior to filling.
2.5 Marking Technology
2.5.1 Marking Technology Industry
The technology around marking nude syringes and vials has existed in some form
since the beginning of the biotechnology industry. Because biologic drugs all look the same
after the many steps of the manufacturing process prior to filling, biotechnology companies
have always been concerned with ensuring the ability for differentiation of product in some
way to prevent mix-up. For example, after a product is placed on the filling line and
dispensed into vials or syringes, the manufacturing personnel have to complete a procedure
called line clearance. Although a commonplace practice in manufacturing, in some ways, it is
much more important for a company like to Amgen to follow strict line clearance
procedures. The procedure even includes clearing the pumping and filling tubes used for that
fill run to prevent cross-contamination.
Marking products at the unit level is performed in many other manufacturing
industries. Food and beverage companies place lot and expiration dates on bottles and
packages. Amgen places that same information on its final, consumer label for every vial or
syringe. In the last two decades, the technology around marking at the unit level has been
primarily basic 1D barcodes, alpha-number codes and simple color-coding on labels or vial
caps. The focus of this research is on marking technologies for nude or product without a
commercial label.
2.5.2 Color Coding
The simplest of the marking methods, color-coding, uses color to distinguish
between products. Figure 5 and Figure 6 below show examples of how syringes and vials
could be color-coded. Another possibility is the color-coding of the plunger or the needle
guard. In any form, color-coding presents an extremely simple solution that is used in many
applications in the biotechnology industry, especially on consumer labels. Many
biopharmaceutical companies utilize this type of
been applied to syringes.
Product A Product B
Figure 5 Examples of
product distinction for vials but has not yet
Product C Product D
Color Coded Syringes
Figure 69: Examples of Color Coded Vial Caps
Despite the simplicity, color-coding has had its bad press in the past. In December
2007, actor Dennis Quaid filed a lawsuit against Baxter, the manufacturer of the Heparin
misused on his twins. According the LA Times, "The lawsuit also faults Baxter for using
similar background colors on the labels of both the high- and low-concentration vials,
despite the possible confusion it would cause."' 0 (See Figure 7.) The point is that color-
coding still allows for human error. Although human error can never be completely
mitigated, color-coding is more susceptible than other technologies to this type of mistake.
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Figure 7": Two Vials of Heparin in the 2007 Quaid Case
Again, looking at nude primary packages, in order to color-code, vial caps will have
to be ordered for specific products. Syringes will also have to be ordered for specific
products. What this does is create product specific raw material. As mentioned previously,
Amgen orders raw material for all products. For example, a 3cc vial or 1mL syringe is
ordered for all products that are filled into 3cc vials or 1mL syringes. Changing this order
process to begin ordering product specific raw material creates three problems:
Problem 1: Risk Swapping
The reason for marking a nude vial or syringe is to prevent a product mix-up or
incorrect label from being placed. Purchasing product specific raw material will only swap
another risk for the current risk. The new risk would be that product A is filled into a
product B syringe. It is difficult to say if the probability of one risk occurring is higher than
the other but the point is, by solving the current problem, another complexity and risk is
added.
Problem 2: Raw Material Procurement Management Complexity
Amgen fills product into a variety of primary packages the most common of which
are 3cc vials and 1mL syringes. Amgen also fills product into 5, 10 and 20cc vials as well as
other primary packages. Already the raw material procurement team has to manage the
ordering quantities as well as frequency of order for each product. If Amgen were to begin
purchasing product specific raw material, the complexity of the management of the raw
material procurement would increase immensely. On top of that, it would provide a new risk
of not being able to procure a particular syringe or vial. Amgen is already in the process of
qualifying a second source for syringes to mitigate that exact risk (among other benefits of a
second source). Figure 8 below is an ordering quantity model of how the complexity would
increase with product specific raw material:
Raw Material Ordering for 3cc Vials for Product A
RMe.rifeVsoAPu
rRaw Material Orderingfor 3cc Vials forAll Products
Raw Material Ordering for 3cc Vial for Product B
Figure 8: Raw Material Ordering Complexity Model
Problem 3: Increased Safety Stock Required
Increasing the number of different types of raw materials needed for production by
marking or color-coding at the vendor would increase the complexity and amount of
inventory needed to achieve a given service level." The reason for this increase is due to how
the total inventory is calculated. Total inventory is function of operating inventory as well as
safety inventory. The amount of inventory held is more a function of risk mitigation
than a response to demand volatility in the market. Even if the assumption is that with
the increased number of types of raw material the operating inventory will not increase, the
safety inventory will. Safety inventory or safety stock is defined as follows:
Iall 
- Z Xo is afe ty ~ (LTD 1
where z = service level and (Y = standard deviation of lead time demand
Because "the total inventory required to provide a specified level of service increases by the
square root of the number of locations in which it is held"", the assumption here is that the
same holds true for the number of raw material types. Therefore, assuming 8 different
products, the new formula derives from the above equation and will approach the following:
~8 ZXV LTD
safety
The increase in safety inventory for Amgen would be about 280% and is approximated by
the graph below:
Safety Inventory vs Number of Raw Material Products
0
C
0
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Number of Different Raw Material Products
Figure 9: Square Root Law applied to Multi-Raw Material Products
Despite the obvious application and simplicity of color-coding as a solution for
marking nude vials and syringes, the problems outlined above outweigh any risk mitigative
benefits this solution would provide. Therefore, it was not analyzed any further as a viable
option.
2.5.3 Inkjet
Technology developed in the 1950s and applied to printing in the 1970s, inkjetting
has been used as a solution to nude vial marking for decades. Typically, ink is jetted onto the
side, the top or the bottom of vials in the form of barcodes or alphanumeric codes. Inkjet
technology is inexpensive in comparison to other solutions. It is also an industry-tested
solution, at least for vials, and therefore, systems are essentially turnkey and ready for
application. Despite their use in the industry for vials, inkjet technology has several
drawbacks. The fill and finish process of biologic drugs is performed in Class 10,000 clean
rooms and having a solution that is spraying microscopic droplets of ink at the surface of the
glass is less than ideal. Also, due to siliconization process variation upstream at the supplier
of the glass syringes, silicon oil is sometimes present on the external surface of syringes,
making it almost impossible to get the ink to stick consistently. The consistency is important
in an industry where six-sigma quality is in some situations not high enough. With tens or
hundreds of millions of units being produced each year, a solution must be extremely
accurate as well as precise. Currently, many biotechnology manufacturers including Wyeth
employ inkjet technology for vial marking. Below is an example of a vial with a standard
inkjet 2D matrix barcode:
Figure 10: Inkjet 2D Matrix Barcode
2.5.4 RFID
RFID or Radio Frequency Identification is an automatic ID technology that utilizes a
tag to track objects using radio waves. Tags contain an integrated circuit and an antenna so
as to be able to store information as well as transmit a signal. RFID is being used in
applications from asset tracking to toll collecting to animal tagging. MIT Mechanical
Engineering Professor Sanjay Sarma comments "RFID systems are different from other
means of identification because RF communication is non-contact and non-line-of-sight,
whereas other means of identification are either contact-based or require line-of-sight."" See
Appendix 9 for a summary of RFID versus barcodes. Factors that limited its use such as size
and cost are quickly becoming problems of the past.
In 2004, Accenture completed a study of RFID application to the biopharmaceutical
industry: "Findings, based on shipping, tracking and tracing nearly 13,500 packages of
pharmaceuticals over an eight week period, show that EPC/RFID can help satisfy regulatory
and retailer requirements, increase product security and consumer safety, enhance order
accuracy and labor productivity and increase the efficiency and speed of recalls and
returns."15 Investments in RFID have increased and, in a large way, have come in the form
of mandates in the last five years. In 2005, Wal-Mart required its top 100 suppliers to place
an RFID embedded label on all shipments to Wal-Mart. The Department of Defense has
also mandated the use of RFID for asset tracking on packages. This massive investment,
although not the silver bullet for supply chain management as previously thought, has driven
increased innovation and reduced tag costs. For example, the costs have decreased at a
similar pace to PCs as seen in this adaptation of Richard Moscatiello's price prediction
model for RFID. The model is simply that, a model; but the model reflects the reality that
RFID tag costs are coming down.
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Figure 1117: Adapted RFID Price Point Prediction Model
Even with size and cost becoming less problematic, there are still prevalent conerns
about privacy, especially when applied to prescription medication. Despite this, Purdue
Pharma, manfacturer of the pain killer Oxycontin, currently uses RFID to track its bottles,
specifically to reduce counterfeiting and shrinkage. "In a recent development, West
Pharmaceuticals and Tagsys USA have incorporated an RFID device into the Flip Off seal
of an aluminum cap for parenteral products."' 8 It hasn't yet been applied by biotechnology
manufacturers but remains an attractive option for marking nude product with the added
benefits of track and trace as well as anti-counterfeiting. Finally, for biotechnology
manufacturers, there is concern that the sensitive proteins in the biologic drugs will
experience a "potential product temperature increase when the RFID tag is exposed to the
electromagnetic energy of the UHF RFID reader for extended periods of time."
2.5.5 Laser Marking
Laser marking is a technology in which a laser is used to burn a mark into a
substrate, which, in this case, is glass. Laser marking is an attractive solution compared to
inkjet because it is much cleaner, potentially faster and more permanent. Laser marking on
glass generally comes in two forms: (1) marking on the outside surface on the glass and (2)
marking on the inside of the glass. Several types of lasers are used for glass laser marking
from CO 2 to YAG to ArF. Each has its specific uses for particular applications or glass
types.
Figure 1219: Examples of Laser Marking on Glass
Laser marking has been considered as a marking option for a long time. Lasers are used to
etch lot number and expiration date onto commercial labels but have not yet been applied to
any biotechnology manufacturer's fill and finish operation for marking glass. Despite lower
maintenance and higher reliability numbers over inkjet technology, the concerns of increased
glass breakage along with worry of deleterious affect on protein stability have precluded any
real industry adoption.
2.5.6 Clear Label
Labels are placed onto every syringe and vial headed for consumer use. Another
technological solution to marking nude product that is shipped to internal sites or external
companies is to apply a clear label with some sort of distinguishing mark, which at a
minimum would denote one product from another. A leading biopharmaceutical company is
using this technology for their brand name vaccine. Not only has it proved successful at
marking each syringe, it yielded a secondary benefit of reducing syringe glass breakage. There
are several incentives for the application of clear label technology versus other technology
solutions. First, labeling is a core competency of biotechnology companies as it is an action
performed millions of times per year within the firm. Second, it allows use of capital
equipment already owned by the company. Lastly, at least in the short term, it is significantly
lower cost even on per unit basis. Although only one biotechnology firm in the industry uses
clear label technology, it has immense potential as a solution to marking nude product.
2.5.7 Technology Advancements
2.5.7.1 "LaserJet" Ink Ribbon Technology
LaserJet ink ribbon technology is a modern innovation on applying ink to glass
substrates. A consumable ribbon of ink is passed in front of laser, which is fired on the
ribbon in the correct pattern to deposit the mark on the glass. Developed by Panasonic in
conjunction with Tesa, the technology claims near indelibility of the mark on the glass along
with no mess. As a marking solution, the laserjet mark could yield the benefit of the
indelibility of a laser mark without the potential for microscopic glass damage. A potential
issue of this technology is whether the ink will adhere to the glass in a robust and repeatable
manner.
2.5.7.2 Plastic Resin Syringes and Vials
Although currently used in the Japanese biotechnology industry, plastic (cyclic olefin
polymer) syringes and vials are not currently used as primary packages in the US. Long-held
concerns of leachable materials in the plastic compounds have kept the application of the
technology from the industry. With an already complex regulatory process for FDA
approval, companies also have a lower incentive to try for approval of an entirely new
primary package for their drugs (which would require years of protein stability studies and
millions of dollars). But, increased pressure from the FDA and EMEA to reduce preventable
glass breakage to zero along with new innovations in plastic compounds is making the idea
of plastic syringes for biologic drugs much more attractive to a manufacturers. The presence
of plastic syringes and vials would not only reduce waste from preventable breakage but it
would also reduce the need for complex packaging during transport. Along with those
benefits, it would also make marking syringes and vials simplistic. Most, if not all, of the
issues with inkjet and laser marking technology would disappear because of the physical
nature of plastic. In short, the use of plastic syringes and vials by a biotechnology
manufacturer would allow for their choice of technologies with many fewer concerns.
Figure 1320: TopasTMI Cyclic Olefin Copolymer Syringes and Syringes
3 Hypothesis
Applying marking technology to internal operations can both mitigate the potential
risk as well as alleviate future regulatory pressure, domestically and internationally. Marking
technology, although requiring capital investment, is a key component in a sustainable,
competitive business operation for a biopharmaceutical company like Amgen. Specifically, in
evaluation of current marking technologies, applying a specially designed clear label directly
after fill presents a low-cost, near-term solution that will:
* Reduce risk of product mix-up
* Increase brand protection
* Increase flexibility to use external final labeling contractors
4 Methodology
4.1 Data Collection and Analysis
Lab scale testing, data collection and analysis were performed at Amgen's corporate
headquarters in Thousand Oaks, CA. Three labs were primarily utilized: the Device Lab, the
Technology Transfer Lab and the Transportation Simulation Lab. However, some of the
testing was performed at various supplier sites and the data will denote that fact.
Because of the broad business implications marking technology could have across
several corporate functions, interviews were conducted across Amgen to understand all
facets of the problem and its likely affect. From supply chain and manufacturing to raw
material procurement and finance, a broad swath of views were studied about marking
technology for risk management in the supply chain.
For practical purposes, testing was completed on a lab scale. Even on a lab scale,
some of the equipment necessary was expensive. Where appropriate, the supplier performed
testing and data was shared to highlight the different issues with different technologies.
Specifically, three technologies were chosen after working closely with the process
development and DP&DD teams. Each of those technologies is presented in later chapters
with thorough analyses about their feasibility to be incorporated into Amgen's current
operations.
4.2 Project Methodology
The project methodology roughly followed the DMADV model.
Figure 1421: DMADV Model
Define - Understanding the problem and the processes involved in marking a syringe or
vial in Amgen's current operations. Figure 15 is a basic value stream map of the entire
process, beginning immediately after the fill-finish process. The red boxes denote the
defined areas of this project.
Figure 15: Value Stream Process Map
Measure - Having researched the many options available for marking syringes and vials,
customer needs and specifications are measured against options to determine best fit.
Analyze - Each of the three selected options is lab scale tested to answer key unknowns
about the technologies in relation to their application to the process.
Design - The final technology is theoretically applied to the process, using implementation
analysis to determine fit and potential problem areas.
Verify - The performance of the final solution is checked and relevant stakeholders verify
the solution.
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4.3 Decision Framework
The list of technological solution options presented in the Chapter 2, although not
exhaustive, is representative of the state of the industry. A framework was created to help
analyze the multiple variables against the multiple options. Using multi-attribute utility theory
(MAUT), a decision model was created to better understand the whole picture. "Multiple
attribute utility theory provides a set of techniques for accomplishing two tasks: (1)
quantifying the utility derived from individual attributes and (2) combining the utility from
each attribute to arrive at an overall measure of utility."2 2 It is a simple, elegant way to
quantify qualitative attributes and decide between multiple solution options in any situation.
TABLE 8.1 The Utility of Strategies to Improve Typing Ability
Altribute
A'lternative Speed /Aturcy Applications utdiy
Large group television 24 49 21 31.7
presentation
Large group lecture 39 65 34 46.6
Teacher-based tutorial 95 69 80 83.6
Computer-based tutorial 87 83 41 76.9
Importance weight 0.48 0.33 0.19
$OURCE Adapted from Lewis (1989.
Figure 1622: Example of Multi-Attribute Utility Theory
As shown in Figure 16, each attribute receives a weighting score depending on that
attributes relative importance to the overall utility. Developed in conjunction with subject
matter experts at Amgen, the attributes shown in Table 2 below are representative of the
most important areas of consideration for evaluation of marking technologies. It is
important to note the limitations of multi-attribute utility theory. If a given decision has too
many attributes (i.e. more than 10), it will be difficult to weight each attribute significantly to
see differences between different options. Therefore, the list of attributes for marking
technologies is not exhaustive. Rather, it is a summation of the few most important
attributes that may contribute to an options' long-term success.
Table 2: Multi-Attribute Utility Theory Attributes
Attributes can be divided into two categories for this type of decision analysis:
qualitative and quantitative. Capital cost, ongoing cost and scalability are the only attributes
that are quantitative. Scalability is a quantitative measure of cycle time and overall complexity
of reading the mark. The results of the multi-attribute utility theory model are presented in
Appendix 10.
Attributes Description
Marking Efficiency Cycle time and simplicity of marking
Capital Cost Total fixed cost to procure equipment
Ongoing Cost Consumable and maintenance costs
Supply Chain Effect Solution impact on current supply chain
Ease of Implementation Implementation simplicity
Ability of technology to be scaled to larger
Scalability volumes
Risk inherent in the technology applied to
Risk the process
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5 Laser Glass Marking: A Technical Evaluation
This chapter presents the strategy and tests performed during the evaluation of glass
laser marking as a potential solution to mark syringes and vials. The tests were completed at
both Amgen's laboratory as well as at the vendor's site.
5.1 Laser Marking Lab Scale Evaluation Strategy
The objective of the lab scale testing is to determine if laser marking is a feasible
solution given the current fill-finish processing techniques used in the industry. Feasibility
for this and all other technologies relies on the following factors:
1. Cycle time of laser marking process is not prohibitively low so as to create
a bottleneck in the current fill and finish process
2. No affect on primary package structural integrity and container closure
integrity (CCI) as compared to a control sample of unmarked syringes
3. No affect on protein stability for any of Amgen's drugs
Amongst glass and biotechnology-manufacturing experts, the key unknown of this
technology is whether laser marking will create micro-cracks in the glass due to the
immensely localized heating and cooling at the location of the mark. Amgen's tolerance for
glass breakage rates is extremely low. Rates at even a few parts per million are enough to
create problems for a manufacturer with the FDA. Therefore, if laser marking were to
increase glass breakage during processing, it would be an unsatisfactory solution.
In Loch and Krause's MathematicalSimulation In Glass Technology, the theoretical view
of micro-cracks as a result of laser marking in borosilicate glass, the type of glass used to
manufacture biopharmaceutical vials and syringes, looks like the figure below:
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Figure 173: Estimate of Localized Laser Heating and Forces Created
Theoretically, laser-marking glass will cause micro-cracks if only at a microscopic level. A
battery of tests was performed to yield significant data to prove the viability of laser marking
as a solution. The tests combined testing done at Amgen as well as tests performed at
vendor and peer firm sites.
Laser marking onto a glass substrate is a difficult task to achieve in a reliable, non-
destructive fashion. Mechanical Engineering Professor David Parks of MIT remarks, "[there
are] at least two issues which need to be addressed: one is the possibility that the laser
marking inducing micro-cracks. A second possibility is that the rapid thermal transients of
the marking manages to impart local residual stress that, if significantly tensile, could also
become problematic." The "problematic" aspect of residual stress for this industry is that it
could cause latent failures in the field where they are the most damaging. Even a
tremendously small field failure rate can be cause enough to spark an FDA recall. To
illustrate the complexity of laser marking, for example, one vision and laser supplier had
immense difficulty with exactly the problems Professor Parks outlined. Below is a picture
from a vial barrel after a laser mark was performed at the supplier's facility:
Figure 18: Vial Barrel Surface Cracking induced by Laser Marking
Particular notice should be paid to the blistering along with the cracking at the
surface of the vial. Furthermore, this test was done to a static vial in a clamp in a controlled
laboratory test. The reality is that laser marking not only has be successful in a laboratory but
also in a fully functioning commercial-scale biotechnology manufacturing facility with vial
and syringe processing speeds up to 400 or 600 units per minute. The technology to be
applied in this situation is a tool and should not hamper the firm's ability to conduct
business nor should it increase the product risk. Laser marking is in some ways as much an
art as it is a science. With subtle and minute differences between glass formulations, devising
a laser solution is indeed a monumental task; too much power and the glass will blister and
crack as in Figure 18 above. Also, too long or too short a wavelength will lead to too much
absorption or too much transmission of the laser light, which then could damage the protein
inside.
5.2 Lab Scale Tests
Given the discussion and results above from some suppliers, a main supplier was
used for all laser marked material in the following lab tests. The tests were devised to answer
unknowns about the technology as well as address areas of testing that had not already been
completed by the supplier. The main supplier is Frewitt Printing SA, a Swiss company that
designs and manufactures "security marking systems designed to prevent counterfeiting
(track and trace system) and to guarantee a 100% traceability of products."24 Specifically,
"Frewitt has developed a laser marking system using a low energy laser to engrave a [2D]
Data Matrix code directly on the glass syringe barrel. Seidenader provides the high-speed
vision system and illumination technique to verify this type of code reliably." 24 Frewitt is the
only supplier in the industry that has shown reliable and repeatable results in marking
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biopharmaceutical glass at production speeds. Data and graphs from Frewitt's testing in
conjunction with other firms in the biopharmaceutical industry can be found in Appendix 4.
The following sections are the results and discussion of both qualitative and
quantitative testing of Frewitt laser marked syringes in various laboratories at Amgen Inc.
Tests were designed with help from Amgen glass experts, Frewitt employees and other
industry professionals.
5.2.1 Qualitative Microscopy
In order to understand possible gross effects of the laser marking, microscopy was
performed on a large number of marked syringes as well as vials. From a qualitative
perspective, "When stress is applied to a material internal strain results. With transparent
materials [such as glass], strain often results in regions of optical activity. Essentially, waves
of light passing through these regions are more or less twisted (i.e., go through a sort of
change in their orientation) by the optical activity. ,2' Thus, the purpose of microscopy is to
determine location and possible level of 'optical activity'. Although the presence of strain
regions is not conclusive in the absolute sense, it does yield a significant amount of
qualitative understanding of the nature and location of the strain in the glass.
The testing setup consisted of a 500x microscope combined with lights, a camera
and a polarizer. A polarizer takes mixed polarization light and converts into a uniform
polarization, allowing the ability to see the changed direction of light passing through
transparent materials. Each of the 200 standard Becton Dickinson (BD) syringes is analyzed
using both standard and polarized light. In looking for the regions of optical activity, an
Amgen glass expert recommended looking for specific 'bright' spots, as these spots were
indications of increased stress in that location. Under standard light, the laser mark across all
samples appeared as it does in Figure 19 below:
Figure 19: Microscopy of Laser Mark under Standard Light
It is important to note the location of the laser mark from the Frewitt system. The previous
supplier with the blistered glass mark in Figure 18 applied the laser mark to the surface of the
syringe. Frewitt actually embeds the mark inside the wall of the syringe or vial using unique
combination of wavelength and power. As a point of clarification, refer to the not-to-scale
Figure 20 below of a wall of a syringe or vial:
Outer Wall
Laser mark
Irmer Wall
Figure 20: Location of Laser Mark in Glass Wall
The location of the Frewitt laser mark has benefits and drawbacks. Given the nature of the
process the Frewitt system would be placed into (i.e. biopharmaceutical processing), marking
inside the wall of the glass produces less byproduct than marking on the surface. According
to Frewitt, 0.5mg of glass particles are produced per 1 million codes. The drawback is the
potential for increased internal stresses that could lead to crack propagation during handling
or transportation. Sections 5.2.2 through 5.2.4 are lab scale tests that attempt to answer of
there is any increased risk of breakage during handling and transportation.
An example of the laser mark seen under polarized light can be seen in Figure 21
below. Notice the red arrows pointing to areas of increased optical activity, which manifests
itself as almost blurry areas surrounding some of the dots of the 2D matrix.
Figure 21: Polarized Image of Laser Mark
Throughout the microscopy analysis of each marked syringe, it was clear that these areas of
increased optical activity were signs of enclosed stress. In the words of an Amgen glass
expert, "With the polarizer, you can certainly see the areas of enclosed stress in the laser
marked syringe, but that doesn't say anything as to the amount or whether it would actually
increase breakage on the manufacturing line".
During the analysis of each syringe, surface pitting was found on about 1% of
syringes. The pitting appeared to only be present above marked areas as in the picture below
on the left below. The picture on the right is a picture of the same syringe this time with the
metal tip of a needle pushed into the one of the pits in the surface. The area clearly lights up
showcasing the increased stress from the surface pitting.
Figure 22: Surface Pitting on Laser Marked Syringes
The results of the microscopy study are a confirmation of areas of increased localized
internal stress due to the laser mark. Although not conclusive in terms of the amount of
stress, the study validates assumptions of the internal stress and necessitates the further
testing to determine the effect, if any, the mark has on the structural integrity of the syringe
or vial. Despite a small percentage, the surface pitting seen in 1% of the syringes is also of
concern.
5.2.2 Fracture Force Testing
The purpose of this lab scale test was to determine if the enclosed stress of the laser
mark would increase breakage during processing. Of particular importance is a processing
step in which a mechanical arm picks up each syringe using mechanical fingers placed inside
the top of the syringe. Both Wyeth and Frewitt performed a number of tests including
shock, compression, handling and thermal cycling. The results of these tests are presented in
Appendix 4-6. What those tests did not include was a study of the effects of internal
compression on marked and unmarked syringes to determine if there was a statistical
difference, which the tests below did address.
The test set-up consists of a precision force inducing and recording device, in this
case an Instron "machine. The syringe was loaded onto a cylindrical gauge above the circular
table of the machine. The end of the gauge corresponded to the location of the mark. A total
of 100 marked and 100 unmarked syringes were broken in this test to obtain a statistically
relevant amount of data. The test set-up can be seen in Figure 23 below:
Instron
syninge on head
gauge
Figure 23: Fracture Force Test Set-Up
The results of the tests are broken into two parts. First, individual breakage results were
examined qualitatively. The graph in Figure 24 shows an individual breakage curve. What can
be seen is a section of elastic deformation or bending followed by catastrophic failure of the
glass syringe. The syringe absorbs the energy during the initial push of the machine to its
maximal point before the energy is released in breaking. Second, the total results were
tabulated and analyzed for standard deviation. The data from all 200-syringe breakage tests
were tested to determine if a statistical difference could be found between the marked and
unmarked syringes.
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Figure 24: Individual Breakage Graph
The picture below shows the result of the breakage during testing. As can be seen,
the breakage happened in a catastrophic fashion with pieces of glass flying out in all
directions from the test area. Appropriate precautions were made to ensure the safety of the
tester as well as all lab personnel.
Figure 25: Catastrophic Glass Breakage during testing
The results of the entire study can be found in Table 3 below:
Fracture Force Test Results
Unmarked Marked
Mean 37.7595 37.7357
Standard Deviation 0.1510 0.1271
Table 3: Testing Results
Using a basic t-test to determine if the difference in the two means in statistically significant:
t = UM ~ M
S
where
(S= UM ) 2 + (aM) 2
N
Calculating the appropriate values yields a t-value of 0.853, which means that the difference
between the two means is not statistically significant. Thus, according to this test, there is no
statistical difference between a syringe that has been laser marked and one that has not been
marked. It is important to note a few key factors that relate to the sensitivity of this analysis.
Given the high volume nature of the biopharmaceutical industry, a sample size of 100 is
relatively small. What this means is that given a larger sample size, the effective difference
between the two means could be more significant. Also, the data shows that there is a small,
albeit statistically insignificant difference between the two means, it would seem natural to
assume that the difference is 100% correlated with the laser marking. Although it is likely
that it is true, given again the relatively small (>100) sample size, it is possible that glass-
manufacturing variation accounts for the difference. Because this is not an industry standard
test, there is not data available to test this secondary hypothesis.
5.2.3 Transportation Simulation Testing
The purpose of this lab scale test is to determine if the laser mark creates increases
susceptibility to breakage in transportation. The standards organization for transportation
simulation and testing is the ISTA. "The International Safe Transit Association is an
organization focused on the specific concerns of transport packaging, and ISTA test
procedures define how packages should perform to ensure protection of their contents. Use
of ISTA test procedures reduces risks in the transport environment and increases confidence
in the safe delivery of a tested packaged-product."26 More specifically, the lab scale tests
performed were in accordance with:
ISTA 3 Series: General Simulation Performance Tests. Designed to provide a
laboratory simulation of the damage-producing motions, forces, conditions, and
sequences of transport environments. Applicable across broad sets of circumstances,
such as a variety of vehicle types and routes. Characteristics will include simple
shaped random vibration, different drop heights applied to the sample package,
and/or atmospheric conditioning such as tropical wet or winter/frozen.
Procedure 3A: Packaged-Products for Parcel Delivery System Shipments 70kg (150
lb) or less (standard, small, flat or elongated) Test Procedure 3A is a general
simulation test for individual packaged-products shipped through a parcel delivery
system. The test is appropriate for different package types commonly distributed as
individual packages, either by air or ground.26
The tests were conducted at Amgen's Transportation Simulation laboratory.
5.2.3.1 Vibration Simulation Testing
The vibration simulation is a test model to simulate the vibration forces experienced
by the packaging and product in trucks or planes. The methodology behind the test was to
package both marked and unmarked syringes in standard packaging and place it on the
vibratory table for the prescribed amount of time to determine if there were any instances of
glass breakage.
Figure 26: Vibration Table
Figure 27: Vibration Table Cycling Chamber
TesQ ID: Seceed PackagingTs
Profle ID: ISTA 3AOerthe-Rnd Traier
0Gh1
0.1
0.01
0.0001
10-005
le-006
Dmd:S 0 554 G rms - 100.0%
Figure 28: Vibration Simulation Model Screen Shot
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The test results are as follows: 50 marked and 50 unmarked syringes identically packaged and
tested according to ISTA 3A transportation standards yielded zero broken syringes. See
Appendix 7 and 8 for more detailed views of the graphical outputs of the vibration
transportation simulation.
5.2.3.2 Drop Testing
The purpose of drop testing is to simulate shock events created by transportation
and imperfect handling. A free-fall drop tester is used for these tests, like the one below at
Amgen:
Free4a drop ester
Figure 29: Amgen's Free Fall Drop Tester
As previously mentioned, the testing was completed in accordance with ISTA 3A
procedures. For free-fall drop tests, testing follows the table below:
The drop test yields a binary response of either unbroken (0) or broken (1) and does not
yield any finer granulation of data related to the exact amount of stress placed on the glass
syringe from the shock pulse. The results from the three replicates of the test are that zero
syringes (marked or unmarked) broke or cracked.
5.3 Technical Summary of Laser Marking
This chapter focused on a methodology of mechanically testing a biopharmaceutical
primary package to determine the potential affects of laser marking technology on the
structural integrity of the glass syringe. From a technical standpoint, laser marking is an ideal
solution as it can mark every syringe at processing speeds and additionally create a source of
anti-counterfeiting at a very low cost per unit. Although processing speeds and read rate
accuracy are in the range necessary for application to biopharmaceutical fill-finish processes,
the structural testing as to the structural impacts on the syringe remain inconclusive. Given
the focus on risk mitigation in this business and industry, large-scale studies would need to
be executed to ensure that this technology did not introduce unintended breakage.
ISTA 3A Drop Test Procedure (Resource Book 2007)
Drop Drop Height Drop Height Drop
Number <70 lb 70-150 lb Orientation
1 18in 12in Edge 3-4
2 18in 12in Edge 3-6
3 18in 12in Edge 4-6
4 18in 12in Corner 3-4-6
5 18in 12in Corner 2-3-5
6 18in 12in Edge 2-3
7 18in 12in Edge 1-2
8 36in 24in Face 3
9 18in 12in Face 3
10 18in 12in Edge 3-4
11 18in 12in Edge 3-6
12 18in 12in Edge 1-5
13 18in 12in Corner 3-4-6
14 18in 12in Corner 1-2-6
15 18in 12in Corner 1-4-5
16 36in 24in Face 3
17 18in 12in Face 3
Fiaure 3026: ISTA 3A Drop Test Procedures
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6 RFID: A Technical Evaluation
This chapter presents the strategy and tests performed during the evaluation of RFID
as a potential solution to identify syringes and vials at the unit level. The tests were
completed at Amgen's Technology Transfer laboratory.
6.1 RFID Lab Scale Evaluation Strategy
The objective of this chapter is to determine the feasibility of RFID as a solution for
marking syringes and vials at the unit level. The factors for success listed in Chapter 5.1 are
also relevant here yet with a different focus. For laser marking, the most important factor
was the potential impact on the glass structural integrity. With RFID, the focus of the lab
scale testing is primarily the first factor but specifically on read rate and read accuracy. An
analysis conducted several years ago had a read accuracy quoted at approximately 80%. In an
extremely high volume environment, 80% is completely unacceptable where the idea to is
simplify the marking and reading process. Therefore, the strategy of this technology
evaluation is to test the hypothesis and assumption that RFID technology cannot sustain the
read accuracy necessary for biopharmaceutical processing. Certain aspects of biologic drugs
are concerning for the application of RFID. Typically, the presence of water and/or metal
can hamper read accuracy. The testing will be set up as a design of experiments to determine
if there is any interaction of these factors on the response of read accuracy.
With RFID as a technology solution, there are two other important factors to
consider. The first (Factor #3 in Chapter 5.1) is the concern about possible deleterious
affects the electromagnetic field can have on the stability of the sensitive biologic products
like Amgen manufactures. A plethora of research both in industry and at Amgen has been
performed in relation to this concern. See section 6.3 of this chapter. The second is potential
for supply chain benefits in the application of RFID. See section 6.4 of this chapter.
6.2 Lab Scale Testing
The laboratory testing utilized a main supplier for the RFID equipment and a
separate supplier for the RFID tags. The RFID equipment was purchased through
ThingMagic, Inc. from Cambridge, MA. The test equipment was setup as shown below:
Actual Lab Setup
Figure 31: RFID Test Data Capture Setup
ThingMagic also provided the software called ReaderAssistant that was used to record the
testing. See Appendix 3 for an example of the software output.
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The RFID tags were purchased through Avery Dennison (AD) RFID Division. The tags are
wet-inlay (adhesive) 16x1 6mm and 1Ox2Omm tags. In the past, companies have had issues
with antenna breakage due to the small diameter of the syringe. Although antenna breakage
was not seen in testing, adhesion to the syringe and vial barrels was difficult. Even if the
labels had adhered perfectly, it is unlikely any biopharmaceutical company would want their
vial looking like the test setup vial:
Figure 32: AD RFID Tag and Vial Test Setup
The testing was performed to determine the affect of three factors on read accuracy.
The three factors are belt speed, water presence in the form of WFI and metal presence in
the form of the metal vial crimp seal. It was assumed that the dielectric properties of the
typical biologic drug are the same as the dielectric properties of water. Therefore, a design of
experiments (DOE) was set up for the test. Because there are three factors and two levels
for each factor, the number of runs is equal to 23 or eight runs to test all combinations and
run a full-factorial design with two replicates.
Factors
Run Belt Speed WFI Metal Cap
1 50% Yes Yes
2 50% No Yes
3 50% Yes No
4 50% No No
5 100% Yes Yes
6 100% No Yes
7 100% Yes No
8 100% No No
Table 4: DOE Run Setup
The belt speed percentage was on the dial of the machine. In order to understand what that
percentage corresponded to, a vial was moved along the conveyor with a ruler to determine
the distance traveled in a given amount of time. The 50% speed corresponded to the vial
moving 48 inches in 9.56 seconds or about 25 ft/min (25 ft/min 200 vials/min). The vial
spacing of 1.5 inches (center-to-center) corresponded to the spacing on the commercial
manufacturing line.
Figure 33: Vials on Conveyor with Spacing
The antenna used for the test was a Laird Technologies Omni-directional 880-960MHz
Antenna (3dBi). The antenna connected directly into the reader.
The test setup in the Technology Transfer Lab is shown in the picture below:
Figure 34: RFID Lab Test Setup
The results of the lab scale RFID test are as follows: 100% read accuracy in every run. What
did vary in the results was the total volume of tag reads as the factors changed, though it is
not clear that there is relevance to total tag reads. The graph and chart below summarize the
results:
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Figure 35: Read Rate Accuracy
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Figure 36: DOE Testing Results
The ThingMagic Mercury 5e RFID reader is rated for a maximum of 170 tag reads per
second. The results are clear that 100% read accuracy is possible. As mentioned in Chapter
5, it is important to note the sensitivity of this test. The test is a relatively small number of
tag reads compared to volume of product Amgen produces and sells every year. But looking
at Figure 36 results, it is clear that belt speed seems to reduce the total volume of reads by a
similar amount for all three scenarios. The addition of WFI seems to cause the largest
variation in total reads, most notably at the lower speed. Notice that a third and lower speed
was tested to check for any added differences.
6.3 RFID Effects on Biopharmaceuticals
The biopharmaceutical industry has an aversion to technological solutions of any
kind that could affect the stability or efficacy of their biologic drugs. Although the effects of
RFID on biologic drugs are not completely understood, many tests have been completed to
specifically determine the thermal effects of the RF field. The FDA, Amgen and the
consulting firm Accenture have all completed tests of the thermal effects of RFID on drug
temperature and stability.
To better understand the variables involved with specific dielectric heating, consider
that "the volumetric power (P) is proportional to the square of the electrical field (E) and the
conductivity (a) of the medium and can be expressed by the following equation 28:
P=aIE |2= 2cfee" | IE 12
Using the energy conservation equation assuming all of the electromagnetic energy is
absorbed by the sample as heat,
pCAT = P - t
where C is the heat capacity of the material and p is density.2"
Substituting the first equation into the second and rearranging for the change in temperature
over the time yields,
AT 2xrfEFE" I E 12
t pCp
Solving this equation for the rate of heating (AT/t) for a 4W UHF RFID system yields the
result of 1.12 x 1010 degrees Celsius per minute. Thus, theoretically, a standard RFID system
should not impart much heating to a vial or syringe contents over the amount of typical
exposure to the RF field, which is usually measured in seconds.27
Industry tests completed saw no thermal effects from the tested UHF RFID
equipment on vials positioned close to the antennas where the RF field strength is the
highest. The FDA saw a temperature rise of O.30C but the vial was exposed to a 22W UHF
field for 7 hours. Also, Accenture saw a 0.5'C but again the vial was exposed longer than
Amgen's exposure time of 4 hours. Accenture's vial sample was exposed to a 4W UHF field
for 16 hours. Despite the FDA and Accenture seeing a temperature rise even in their worst
case scenario's, these are not temperature deviations that of concern to the stability of their
drugs. It was also reported that neither Amgen nor the FDA and Accenture saw any changes
in non-thermal factors of any drug tested. Although the studies seem to suggest that that
RFID is completely safe on biologic drug products, FDA approved stability studies can take
several years for conclusive evidence.
6.4 Potential RFID Supply Chain Benefits
Because RFID allows for NLOS (non-line of sight) reading and has the ability to
store more information than a barcode, it's application to manufacturing and operations can
many times lead to savings from reduced labor, inventory and stock-outs. In other
industries, these savings come from a reduction in total inventory and reduced supply chain
issues like obsolescence, shrinkage and stock-outs. Because biopharmaceutical industry
operations are dominated in a large part by risk mitigation protocols, the potential RFID
supply chain benefits don't really apply (except in the case of some labor reduction). Even if
an RFID system showed the possibility of reduction of inventory, a biopharmaceutical
company would probably not reduce its total inventory, which it keeps to mitigate any
possibility of running out of product. This is an industry that strives to operate with a "lead
capacity policy". Under this type of capacity strategy, "capacity is added before it is needed,
so on average there is excess capacity and demand is always met."" Therefore, although
some savings could be seen, the value proposition of RFID implementation is not as strong
for a biopharmaceutical company like Amgen.
6.5 Technical Summary of RFID
RFID technology offers many benefits over other solutions: the ability to read tags
without direct sight, the ability to store significant amounts of information and potential for
small labor savings involved with reading barcodes. Regulatory bodies such as the California
State Board of Pharmacy and the FDA "envision a drug supply chain in which security is
enhanced by a universal electronic pedigree requirement with full-system track and trace, and
mass serialization at the unit levelwith standardized unique numerical identifiers. Both the
FDA and California prefer, and assume this system will utilize, RFID technology."" Despite
the benefits, regulatory pressures and technological advances. RFID as a solution is still
unlikely to be accepted by biotechnology companies due to the per-unit cost as well as the
lack of an ideal application form to vials and syringes.
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7 Clear Label Application: A Technical Evaluation
This chapter presents the strategy and tests performed during the evaluation of clear
label application as a potential solution to identify syringes and vials at the unit level. The
tests were completed at Amgen's clinical labeling facility.
7.1 Clear Label Lab Scale Evaluation Strategy
The objective of this chapter is to determine the feasibility of clear label application
as a solution for marking or distinguishing unit level vials or syringes. The success factors
listed in Chapter 5.1 are again valid here with the focus on cycle time of the labeling
operation as well as the added labels effect on the overall diameter of the syringe. The reason
this is of concern is due to Amgen's use of a needle safety device generically called a needle
guard. Amgen uses two types of needle guards for their products depending on the
regulatory requirements: a manual needle guard and an automatic needle guard. For a
complete tolerance analysis of a syringe and needle guard, see Appendix 2.
The strategy for the testing was to apply the clear label to a syringe and then run it
through the standard labeling operation to examine the performance of the labeling with an
additional label present. There were concerns the clear-labeled syringe would not fit into the
labeler and additional concerns the clear label would prevent proper adhesion of the final
label. The lab scale testing was designed to attempt to answer these concerns about the
technology as a solution.
7.2 Lab Scale Testing
The label supplier for the lab scale testing was CCL label, which provided custom
labels designed specifically for testing. The custom label was small in all directions. It was
designed to be about 0.002 inches thick and with length and width such that the label did not
overlap itself when wrapped around the syringe. It was also designed to be completely
encapsulated by the second label. Of particular relevance to this testing is the fact that
Amgen completed an over-labeling project on one drug product to extend the expiration
date in accordance with regulatory requirements. There are several issues with over-labeling a
syringe with a commercial label already present. Label manufacturers apply a coat of varnish
over commercial labels to prevent smudging of the text on the label. That varnish creates a
surface that is non-ideal for proper label adhesion by lowering the surface energy. Also, the
original label placed on that syringe has to be designed to be over-labeled from a size
perspective. The registration of the second label has to be perfect in order to match up with
the original label. In the process of the over-labeling project, label flagging, wrinkling and
scuffing can be an issue. The design of new clear label sought to minimize these issues by
eliminating the varnish and by its thinness. Below is a picture of syringes with a clear label
applied:
Figure 37: Clear Labeled Syringes
The label by itself does not distinguish or mark the syringe or vial. Two options are
considered for marking.
1.) UV ink 2D matrix barcode pre-printed by the label supplier
Figure 38: Clear Label with UV 2D Matrix Barcode
2.) Fluorescing yellow ink washed across the entire label only visible with UV light
called Radflour 2040 made by a company called Radcure.
' Radflour Clear
LabelStandard W
Varnish-Free
Clear label
Figure 39: Standard Clear Label versus RadflourYellow Label
An important point to note is the innovation in the design of option 2. Option 1
requires a sophisticated and capital-intensive multi-camera vision system to check for
presence and read the 2D matrix barcode. The ink technology in option 2 has never been
applied to biopharmaceutical labels before but it can be read by a simple, inexpensive vision
system that does a binary check for the particular ink color that can be proprietary for each
product the company produces.
The laboratory test consisted of 100 clear-labeled syringes to be labeled with a final
test label. Following the labeling step, each syringe is to be checked for visual defects
including flagging, wrinkling and scuffing. The labeling machine used is a Groninger, the same
machine used in commercial labeling facilities.
Syringe
In-Feed
Figure 40: Groninger Labeler
7.3 Results and Discussion
The results of the clear label test are shown below in Table 5. Label flagging occurs
when the edge of a label peels up due to lack of perfect adhesion. A label scuff is any foreign
mark on the label that occurs during label operations and handling. A label wrinkle is an
enclosed bubble in the label after the label is applied. The automatic needle guard fit was a
hand fit test where each double-labeled syringe is inserted into the device to check for
acceptance fit.
Clear Label Test Results
Syringes Labeled 100
Label Flagging 2
Label Wrinkling 0
Label Scuffing 0
Automatic Needle 100
Guard Fit
Table 5: Label Application Results
Figure 41: Clear Label and Test Final Label Applied to a Syringe
Figure 42: Automatic Needle Guard Fit Test
Several important notes about the results must be discussed. First, the test was successful.
The testing showed that is indeed possible to place a distinguishing mark on a clear label and
apply a commercial label over the first label. Also, despite the concern of automatic needle
guard fit, all 100 syringes passed a fit test into the device. Second, although there was a 2%
incidence of flagging, the likely cause was human error in placing the clear label.
From a business perspective, the clear label solution offers some key advantages over
the other solutions. The cost of the extra label at large volume (>3million) is about 0.5 cents
per label. That cost is especially low when considering this clear label would only need to be
applied to product being shipped intra-site for sale in the EU or potentially for labeling and
packaging by another company. Add to that the fact that the competency for labeling already
exists within the company, the solution is attractive, especially from a short-term perspective.
Other technologies may improve and eclipse this solution but in the next few years, this may
be the most ideal solution to solve the issue of shipping unmarked vials and syringes.
7.4 Technical Summary
Clear label application is a feasible and attractive solution for marking syringes that
are unlabeled in the supply chain. Testing showed that, at least at a lab-scale, over-labeling of
a custom designed clear label is possible and repeatable. The business implications of this
solution are also positive. Both the cost per label and the cost of the reading equipment (for
option 2) are inexpensive. The competency for labeling exists within Amgen and can be
leveraged to make this an optimized solution, especially in the short-term. Specifically for
syringes, the clear label technology could be applied to vials too. From a technological
maturity perspective, it is more reasonable to apply an inkjet to the vial process as
commercial-off-the-shelf systems are available and are being used for vial marking
throughout the industry.
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8 Technology Advancements
In Section 2.5.7, technology advancements were summarized, showing the direction
of future of the marking industry. In order to fully analyze the entire solution space, two
advanced technologies were looked into with greater depth. This chapter will touch on
LaserJet technology and a few lab scale tests performed to understand the current
capabilities of the solution. The chapter will also consider the future of parenteral primary
packaging, specifically in relation to the potential movement towards plastic.
8.1 LaserJet Technology Analysis and Testing
The purpose of this chapter is to dive deeper into the technology referred to as
LaserJet. The value proposition of this technology is clear. The technology vendor claims
that it is a robust, low-cost, serialized code that does not affect the glass or external
dimensions of the syringe or vial. Working with the supplier, 30 syringes were procured for
some basic testing. The reason the technology is not currently being considered as a
potential solution is due to the status of the intellectual property. The technology was co-
developed between two companies and it looks as though a glass supplier bought a limited-
time right to the technology.
LaserJet is a technology in which a laser is fired at a ribbon that is in front of the
substrate or glass. The laser ablates the ribbon and deposits the ink by-product on to the
syringe or vial. The 2D matrix code looks like the following picture:
Figure 43: LaserJet 2D Matrix Barcode with Human Readable Code
71
Although the syringes in Figure 10 and Figure 43 look similar and are both ink marks, there is
an important difference. Both marks are made with ink, but as will be shown below, the
laserjet mark is virtually indelible whereas the inkjet mark has issues sticking to glass in the
presences of silicon oil.
A significant concern with the technology is the ability of the code to survive the
rubbing and chaffing of processing and shipping. In order to test the robustness of the code,
a laboratory scale test was designed using the Sutherland Rub Tester 2000 pictured below:
Figure 44: Sutherland Rub Tester
Each of the 30 syringes was rubbed for a total of 120 seconds and this was compared to a
standard inkjet mark on a syringe. The results, shown in the graph below, prove the
robustness. After two full minutes of direct on-the-mark rubbing, the code looked exactly
the same as compared to the standard inkjet, which was unreadable after the rubbing. It is
important to note that the graph in is a qualitative expression of the results of the rub test.
Figure 45: Standard Inkjet Mark before Rub Test
Figure 46: Standard Inkjet Mark After Rub Test
Figure 47: LaserJet Mark Before (Left) and After (Right) Rub Test
Rub Testing Comparison
100
90
0 80
C70
00 ......... -n jet
A* -LiUnear~ret
~50
40
30
20
10
0
0 20 40 60 80 100 120 140
Time (seconds)
Figure 48: Rub Testing Qualitative Results
LaserJet technology is extremely robust and a standard, inexpensive reader can easily read
the code. Even when exposed to an alcoholic solvent, the code showed no degradation in
quality. LaserJet technology is certainly a solution that industry should continue to monitor
in the future.
8.2 Plastic Parenteral Primary Package
In the last few years, there has been increased interest from biopharmaceutical
companies in new formulations of plastic compounds used to make syringes and vials. The
'new' compound is a 50-year old plastic composition called cyclic olefin polymer; it is 'new'
in its application to parenteral packaging. Many of largest glass syringe and vial
manufacturers such as Schott and Becton Dickinson have plastic syringes and vials available.
"It is the combination of their clear optical properties and low moisture permeability, high
purity, and bio-compatibility that contribute to their attraction for primary pharmaceutical
packaging."32 (See Figure 49 below.) Indeed, these factors are key in the consideration for use
at a company like Amgen. From an operations perspective, plastic syringes and vials offer
two key advantages over the current glass packages. First, plastic syringes are break resistant
during processing, handling, shipping or even in use by the patient. This prevents costly
errors that create scrap and also potentially eliminates certain quality steps that check for
glass cracks in the current fill-finish process. Second, a plastic syringe would allow for
complete freedom to apply many marking technologies. Laser marking, inkjetting and even
molding in a mark are all options for plastic that do not suffer from the same restrictions as
glass due to the material properties of plastic. It will be important for Amgen to follow the
regulatory movements for plastic syringes, which may be the last big hurdle for their
acceptance. If plastic syringes and vials become a commonplace part of Amgen's process,
their ease of marking nude vials and syringes will greatly increase.
Cvcuc OLEFIN PROPEmES
Cyclic olefins offer the following
properties:
- Glass-like transparency
- High purity (low potential
extractables)
-Very low water absorption and
permeability
- Biocompatibility
- Formulations available as "Medical
Grade (complies with USP Plastic
Class VI)
- Low density
- Broad range of glass transition
temperatures (Tg)
- High heat deflection temperature
(HDT)
-Good resistance to acids and bases
- Excellent insulator (low
dielectric loss)
-Good molding characteristics
including low shrinkage
- High dimensional stability
-Coextrude with other plastics
as film
Figure 4932: Attractive Cyclic Olefin Polymer Properties
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9 Financial and Implementation Analysis
In the previous chapters, the different solutions were analyzed from a technical
feasibility standpoint. Although certainly an important first step, it doesn't take into account
the financial and operational aspects of each solution. This chapter will focus on the
methodology used to calculate the financial impact of each of the solutions on the business
as well as the issues related to actual implementation. The financial analysis will compare the
solutions with each other, utilizing a method of financial study called risk-adjusted net
present value. The implementation analysis will focus on the application of the solution
presented in Chapter 7 to the biopharmaceutical process.
9.1 Methodology for Financial Analysis
Financial data associated with cost modeling is not an actual or perfectly accurate
representation of the costs incurred in applying each solution. Rather, it is a method to
obtain general costs using assumptions to simplify the scenarios. The data obtained here is a
combination of non-binding verbal quotes from suppliers as well as estimates from the
manufacturing and finance departments at Amgen.
Because of the goal of financial analysis is to determine approximate cost numbers
for each solution, the scope of the analysis is limited to processes related to marking and
reading of the coded syringe or vial. The costs that make up the analysis include:
o Capital costs associated with the procurement of equipment needed for making
the mark onto the vial or syringe
o Ongoing operation costs associated with consumables in relation to the marking
solution or technology
o Maintenance costs associated with the upkeep of marking equipment
o Additional labor costs needed to perform the marking step
Additionally, because unit level marking has never been performed at Amgen, several
assumptions had to be made as to the level of additional labor or the cost of maintenance.
Although attempted, peer biotechnology companies were, without surprise, unwilling to
share this type of financial data with Amgen. Other assumptions surround the risk
adjustment of the net present value as well as the number of units being shipped unmarked
between sites.
9.2 Net Present Value Analysis
Net present value is "defined as the value-in today's dollars-of the cumulative
annual after-tax net cash flows directly stemming from the project or product deal."" In
mathematical terms, NPV looks like:
n
NPV = (Benefits - Costs)t
t= (1 + r)t
where:
r = discount rate
t= year
n = analytic horizon (in years)
Figure 5033: NPV Equation
The assumptions for the model include a 3% inflation rate; a 38% corporate tax rate and a
constant year-to-year wage merit increase for labor headcount. Cash outflows were
discounted using the standard rate at Amgen for capital investment projects. Depreciation of
the capital equipment occurred over 5 years using a straight-line method.
Cost estimates for clear label applications are well understood as labeling is a core
competency across the industry.. Laser marking and RFID require slightly larger estimations
given the lack of fully accurate information available for costs related to ongoing operations,
maintenance, and labor. Because of this information shortfall, two cases are considered for
each NPV calculation: a base case and a worst case, where costs are assumed higher for
RFID and laser marking.
Risk adjusted NPV is "adjusted for risk by multiplying cash flows by the probability
that those cash flows will actually occur". The normal use for this type of analysis is for the
valuation of biopharmaceutical products in the pipeline and the probability that the product
will be approved for commercialization. In this case, the risk adjustment will be in terms of
an adverse event related to product mix-up, assuming the unit level mark prevents that
adverse event from occurring. An adverse event is defined here as a product mix-up that is
caught either in house or in the field. Because of the large difference between the costs
associated with an in house find versus an in the field failure, two cases are analyzed. Rather
than product success or failure then, the analysis is focusing on cost avoidance of an adverse
event occurring.
Marking Base Case Worst Risk Risk
Technology NPV Case NPV Adjusted Adjusted
Option ($millions) ($millions) NPV Low NPV High
Laser Marking -3.09 -4.61 -2.06 1.91
RFID -0.74 -1.67 -0.56 4.33
Laser et -0.67 -1.41 -0.52 3.94
Clear Label -0.49 -2.24 -0.35 4.50
Table 6: Net Present Value Analysis for All Scenarios
(Note: Numbers have been altered to protect sensitive data. However, the basic significance has been preserved)
The risk adjustment was made in terms of a best guess scenario for an in house mix-up
discovery where product must be scrapped and for an in the field mix-up where product has
to be recalled. The valuation of those different scenarios in based on industry data as well as
Amgen understanding of internal costs. As previous mentioned, the numbers have been
altered to protect sensitive data.
9.3 Financial Discussion of Technology Options
As can be seen from the analysis above, the clear label technology has the least
negative NPV. The reason the base case for clear label application is the lowest is that it
utilizes current infrastructure. For more discussion about the different options for clear label
technology, see chapters 9.4 and 9.5. Laser marking has the highest expenditure because of
the high cost of capital equipment. Outside of the capital purchase, the laser marking option
could be one of the lower cost options as the per unit costs and maintenance costs are
extremely low.
The business driver for the marking project is risk mitigation with product mix-up.
The costs involved with a mix-up result from scrapped finished goods but also from
potential product recalls. Product safety concerns are most important for the long-term
sustainability of the company's reputation. Therefore, Table 6 shows all negative NPVs for
the base and worst-case scenarios. The project is about risk and cost avoidance, which is
taken into account in the risk adjusted columns.
9.4 Methodology for Implementation Analysis
The purpose of the implementation analysis was to determine the feasibility of the
application of the solutions to the biotechnology manufacturing process. Specifically, the
analysis focused on the fill-finish process. It is important to understand the potential
implementation issues surrounding a particular solution, especially as two of the solutions
would be completely new technologies for Amgen. The focus of the implementation analysis
was on the one solution with most promise for short-term application. That solution, clear
label application, is analyzed given current Amgen space and capital constraints, looking at
product flow throughout the plant.
9.5 Implementation Exercise: Clear Label Technology
In analyzing the application of clear technology to a current manufacturing facility,
two implementation options resulted as potential solutions:
1. Use of existing labeling equipment taking into account capacity
constraints and material flow. Because syringes would come from the fill-
finish area in a rondo tray, the syringes would have to be un-trayed
before clear labeled. Also, in this option, the syringes would be loaded
back into rondo trays manually (although the option exists to re-tray the
syringes using a machine).
Manual Rondo
Tray AreaVi,
Shipping
Untrayer Labcler
Figure 5134: Implementation Option #1 for Clear Label
2. Creation of an entirely new, small clear labeling line. Space would need to
be made available for an area that would be specifically for product that
required a clear label. The benefit of this option is that it would make
material flow much simpler as all products needing a clear label would
simply move to this new line as opposed to using existing equipment.
The drawback is the higher cost of capital as compared to option one
above.
Tayer
Untrayer
Labeler
Figure 5234: Implementation Option #2 for Clear Label
The implementation exercise shows that not only is the clear label option feasible from a
technological perspective but from a manufacturing perspective as well. Implementation
study fleshes out all of the small yet important details involved with a new process such as
material flow, space constraints and labor requirements. Without such an analysis, the
likelihood of actual implementation is much lower. This analysis gives the solution a much
needed depth and understanding of the reality of the actual variables involved at the
manufacturing site.
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10 Conclusion
In a complex manufacturing industry like biotechnology with uncertainties in
product approval and success, risk management is a key component of sustainable survival.
Amgen has proven its success by remaining one of the few biopharmaceuticals who hasn't
gone through a merger or acquisition in the last decade. Nude product in the supply chain,
although current cGMP mechanisms serve Amgen well in ensuring product movement
across its network, presents a potential risk that has implications for product safety and
quality as well as corporate reputation. With a new product about to be successfully brought
to market, other promising products in the pipeline, and increasing international growth, the
need for a solution has never been clearer. In looking at the marking industry, several
solutions are attractive options. Three specific options were analyzed for their feasibility
from a technical, financial and implementation perspective. From that analysis and
discussion, it is apparent that the clear label technology is the most realistic option for short-
term implementation. It offers a low-cost solution that relies on internal competencies but
utilizes new ink technology. Although technological advancements may become more readily
applicable, it properly mitigates the risk without being prohibitively expensive. Applying the
clear label at the point of manufacture mitigates the risk of mix-up as well as reduces
regulatory pressures going forward.
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Appendix 1
Regulatory Frame Work
- CGMP Regulations (FDA) 21 CFR 211)
f 211:130 PackgIng and labeling operatIon*
There slas be written procedures designed to assure that correct labels. labeing. and pakaging materials are used for drug products; such
written procedues shah be folowed. These procedures shall incorporate the following features:
(aPrevesion of mixups and crosscntammabon by physical or spabal separation from operations on oher drug poducts.
b dertiicaton and handlng of fed drug product contaners hat are set aside and held in unlabeled contn for future Lae1ing operations to
preclude misbabehng of indtvidua1 contamners, lots, or potDonls of lots. Identificaton need not be applied to each individual container but shall
be sufficient to determine name, strength, quantity of contents, and Iot or control number of each container.
( entfca of the drug prodct with a lotr cont number that permits determination of thiet manuacure and contro of the
(dExamination of packagng and labeing materials for stabi4ty and correctness before packgng operaions, and documertaton of such
examninationin the batch producio record,
(el Inspecti of tte packaging and labeling faclides immeiately before use to assure that all druq products have been removed from previous
operations,
Inspecton sha also be made to assue that packaging and labekng materials not suidable for subsequent operaions have been removed.
Resuhs of nspecton shafl be dccumented M the batch production records
[43 FR 45077 Sept 29 1978 as arended at 58 FR 41354 Aug, 3,1993J
Appendix 2
Automatic Needle Guard Tolerance Analysis
Automatic Needle Guard
Inner Diameter: 8.6mm t 0.1mm (0.340in ± 0.004)
Range of 8.5 - 8.7mm
Manual Needle Guard
Inner Diameter: 8.63mm ± 0.25mm (0.34in ± 0.01)
Range of 8.38 - 8.88mm
Syringe Barrel
Outer Diameter: 8.15mm 0.1mm
Range of 8.05 - 8.25mm
Clear Label Thickness: 0.06mm (blue)
Commercial Label Thickness: 0.09mm (maroon)
Total Label Additional Thickness = 0.06mm + (0.09mm x 2) 0.24mm
Therefore, total barrel thickness being inserted into needle guard (worst case) is about
8.5mm.
Commercial
Label
Clear Label
Appendix 3
ThingMagic Reader Assistant Software Output
Jhirig a Reader Assistant
ie Edi Optwn Action H1
Reader Te Merry ThingMagic
Readtwrte Confg 5tatus Frmware Ptselec tivperans Special Operations H-ggs Debug_ Regulatry
Reada Ant RSS1 EPC
89
Appendix 4
Frewitt Laser Mark Shock Testing Results
Shock
F9,WIrrL
~...
not marked
invisible
VAvisible
0300
not marked Invisible visible
average [mj 132 131 131
deviation [m)] 44 52 53
20 40 60
50.0
37.5
25.0
12.5
0IUU 120 j IbuI
Energy [mJ]
Appendix 5
Frewitt Laser Mark Compression Testing Results
Compression
not marked
invisible
visible
200 300
s i06(
JU1000 1 0
Force [N] 10
not marked invisible visible
average [NJ 579 593 601
deviation [N] 159 151 152
80
60
40
20
0
" 1300
Appendix 6
Frewitt Laser Mark Thermal Cycling Results
FREWITTI
Prinn
Thermal cycle
* 10 syringes
* -50*C for 30 min
* +150*C for 60 min
* repeat 4x
* no visible effect
i
040 U w nail
"-powier wa *8w 2*gs e P wa
Appendix 7
Vibration Cycling Chamber Settings and Output
Over-the-Road Trailer
Test ID: Seconday Pacaging Test Control 0 560 a ns Elapsed 0
Prot 10 ISTA 3A Over-tie-Road Trader Demand 0$64 G vms -1000% ftemainai: 0
Ch 1
0.1 : - - - ---
0.01 -/
PSD 0.001
.0.0001
le-005 - -
r 29 mn 54 sec Profiet Od 2
nr 0 Mn 5 see Tota: 0 hr 0 mn 0 sec
Frequency (Hz)
.... .... -.- -.- -
--- i
Appendix 8
Vibration Cycling Chamber Settings and Output
Pick-up and Delivery
TestO ID: Secondary Packaging Test Control: 0.460 G rms E
Profi ID: ISTA 3A Pick-Up Deivery Demand: 0.458 G rrns - 100.0% Rem
Econtrol
fCh I
0.1
0.01
PSD 0.001(G2/Hz)
0.0001
10-005
le-006.
iapeed: 0 hr 29 min 54 sec Profile: 0 of 2
ainlng: OhrO min 5sec Total: 0 hr 0 min 0 sec
10 24
Frequency (Hz)
Appendix 9
Bar Codes versus RFID
Bar Code Tags REID Tags
Bar codes require line RFID tags can be read
of sight to be read. or updated without line
of sight.
Bar codes can only be Multiple RFID tags can
read individually. be read simultaneously.
Bar codes cannot be RFID tags are able to
read if they become cope with harsh and
dirty or damaged dirty environments.
Bar codes must be visible RFID tags are ultra thin
to be logged, and can be printed on
a label, and they can be
read even when concealed
within an item.
Bar codes can only RFID tags can identify
identify the type of item. a specific item.
Bar code information Electronic information can
cannot be updated. be overwritten repeatedly
on RFID tags.
Bar codes must be REID tags can be
manually tracked for item automatically tracked
identification, making eliminating human error.
human error an issue.
.BM Center for The Business of Gowrnment
Appendix 10
Multi-Attribute Utility Theory Model Output
The Utility of Marking Technologies
Ahibute
Marking
Efficiency Capital Cost
Ongoing
Cost
Supply Chain
Effect
Fase of
Implcmentation Scalability Risk
Omd
UI*
RFID 35 67 25 85 75 67 50 56.15
Iaser Marking 67 25 85 50 35 67 15 49.45
Laseret 85 50 35 50 45 75 1 85 641.5
Clear Label/Inkjet
Importance Weight
67 80 61.95
Aksaa
0.25 0.1 0.1 0.15 0.15 0.1 0.15
1 025 1 0.1 1 0.1 1 
0.15 1 0.15 1 0.1 1 
0.15
